share_log

Altimmune | 4: Statement of changes in beneficial ownership of securities-Officer Harris Matthew Scott

Altimmune | 4: Statement of changes in beneficial ownership of securities-Officer Harris Matthew Scott

Altimmune | 4:持股变动声明-高管 Harris Matthew Scott
美股sec公告 ·  08/01 17:41
Moomoo AI 已提取核心信息
Altimmune's Chief Medical Officer, Harris Matthew Scott, completed a purchase of 1,486 shares of the company's common stock on July 31, 2024. The transaction was carried out at a price of $5.41 per share, resulting in a total investment of $8,039.66. Following this acquisition, Harris now directly holds a total of 55,119 shares in Altimmune. The transaction reflects a direct ownership in the securities and is categorized as a grant, award, or other acquisition as per the transaction code 'A'.
Altimmune's Chief Medical Officer, Harris Matthew Scott, completed a purchase of 1,486 shares of the company's common stock on July 31, 2024. The transaction was carried out at a price of $5.41 per share, resulting in a total investment of $8,039.66. Following this acquisition, Harris now directly holds a total of 55,119 shares in Altimmune. The transaction reflects a direct ownership in the securities and is categorized as a grant, award, or other acquisition as per the transaction code 'A'.
2024年7月31日,Altimmune医疗公司的首席医学官哈里斯·马修·斯科特以每股5.41美元的价格购买了1,486股公司普通股,总投资额为8,039.66美元。此次收购后,哈里斯现在直接持有Altimmune医疗公司共55,119股,这次交易反映了对证券的直接拥有,并根据交易代码“A”归类为授权、奖励或其他收购。
2024年7月31日,Altimmune医疗公司的首席医学官哈里斯·马修·斯科特以每股5.41美元的价格购买了1,486股公司普通股,总投资额为8,039.66美元。此次收购后,哈里斯现在直接持有Altimmune医疗公司共55,119股,这次交易反映了对证券的直接拥有,并根据交易代码“A”归类为授权、奖励或其他收购。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息